Corient Private Wealth
MIRM icon

Corient Private Wealth’s Mirum Pharmaceuticals MIRM Stock Holding History

Corient Private Wealth’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
13,367
+7,597
+132% +$763K ﹤0.01% 1532
2026
Q1 		$441K Buy
+5,770
New +$543K ﹤0.01% 2099

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's MIRM Position: Q2 2026 in Review

Corient Private Wealth increased its Mirum Pharmaceuticals (MIRM) stake by 132% in Q2 2026, buying an estimated $763K and bringing the position to 13,367 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Corient Private Wealth first reported a position in MIRM in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Corient Private Wealth held 13,367 shares of Mirum Pharmaceuticals worth $1.56M as of Q2 2026.
  • Corient Private Wealth bought 7,597 Mirum Pharmaceuticals shares in Q2 2026, an estimated $763K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1532 holding.
  • Corient Private Wealth first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.